Plutux
$2.20
-1.35%
2026-09-04 09:44:28 EDT+$0.00
Healthcare
Drug Manufacturers - Specialty & Generic
NASDAQ
Active Trading

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) ...

Price Action

$2.20
+0.00%+$0.00
High
Low
52W High-99.3%
Rel. vol
Interval
Range18m
VolumeSMA5SMA10
China SXT Pharmaceuticals, Inc. (SXTC) is a China-based healthcare company primarily engaged in the traditional Chinese medicine pieces (TCMP) industry. The company’s core business is the end-to-end development and commercialization of TCMP products, spanning research and development, manufacturing, marketing, and sales. Unlike a pure distributor model, SXTC is positioned as ...China SXT Pharmaceuticals, Inc. (SXTC) is a China-based healthcare company primarily engaged in the traditional Chinese medicine pieces (TCMP) industry. The company’s core business is the end-to-end development and commercialization of TCMP products, spanning research and development, manufacturing, marketing, and sales. Unlike a pure distributor model, SXTC is positioned as an operator within the TCMP value chain, which typically includes sourcing medicinal raw materials, processing/standardizing them into consistent medicinal “pieces,” and supplying these products to downstream healthcare and retail channels. Product-wise, SXTC’s portfolio includes TCMP items in multiple quality tiers (advanced, fine, and regular) and raw medicinal material offerings. Examples of TCMP products referenced in the company’s description include SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. The company sells through recognized brand lines such as Suxuantang, Hui Chun Tang, and Tong Ren Tang, which are intended to support customer trust and repeat procurement—an important consideration in TCM supply relationships. Commercially, SXTC’s customers include pharmaceutical companies, chain pharmacies, hospitals, and pharmaceutical distributors. In these channels, purchasing decisions often depend on product consistency, regulatory compliance, and supply reliability. From a cost and “BOM” perspective (bill of materials), TCMP manufacturing generally involves substantial inputs tied to raw medicinal materials and processing steps, which can drive inventory needs and working-capital requirements. The provided financial indicators also align with a working-capital-heavy profile: the dataset shows very high days-of-inventory outstanding and a very long operating cycle, which is consistent with inventories and downstream conversion taking time before cash is realized. Financial/valuation context from the provided dataset suggests recent profitability pressure (negative operating/net margins and negative free cash flow metrics), alongside strong reported liquidity measures (e.g., high current ratio/quick ratio). In addition, some cash-flow/coverage ratios appear negative, indicating that cash generation has been challenging in the latest trailing period snapshot. Market capitalization is relatively small (around the low millions USD in the dataset), and valuation multiples provided are also influenced by losses (e.g., negative earnings-based ratios). Key leadership includes Feng Zhou, who has been reported as CEO (and Chairman) since July 4, 2017, and also connected to earlier executive leadership at a VIE entity. Overall, SXTC’s strategy centers on maintaining its traditional TCM brand presence while managing the operational and financial demands of TCMP manufacturing, inventory turnover, and downstream sales execution.
Founded
2005
Employees
56
CEO
Feng Zhou
Full Name
China SXT Pharmaceuticals, Inc.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
ROE
-31.02%
Market Cap
$0.00B
Current Ratio
7.93
WACC
9.96%
ROIC
-20.19%

Contact Information

86 523 8629 8290
178 Taidong Road North, Taizhou, JS 225300

Related stocksDrug Manufacturers - Specialty & Generic

Browse all US stocks

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

© Plutux Technology Limited 2026